Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 39,160 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $219.66, for a total value of $8,601,885.60. Following the completion of the transaction, the president directly owned 1,673,858 shares in the company, valued at approximately $367,679,648.28. This represents a 2.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stephen Hoge also recently made the following trade(s):
- On Tuesday, November 17th, Stephen Hoge sold 39,215 shares of Moderna stock. The shares were sold at an average price of $211.61, for a total value of $8,298,286.15.
- On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40.
- On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The shares were sold at an average price of $213.48, for a total transaction of $8,373,539.52.
- On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22.
- On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67.
Moderna Stock Performance
NASDAQ MRNA traded down $10.01 during trading hours on Wednesday, hitting $196.79. 6,901,633 shares of the company’s stock traded hands, compared to its average volume of 12,504,324. The business’s fifty day moving average price is $204.39 and its two-hundred day moving average price is $98.06. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $79.63 billion, a P/E ratio of -27.72 and a beta of 1.16. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $280.80.
Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same period in the prior year, the company earned ($0.51) earnings per share. The firm’s revenue was up 29.2% on a year-over-year basis. Equities research analysts predict that Moderna, Inc. will post -5.14 EPS for the current year.
More Moderna News
These are some of the MRNA news items that stood out recently:
- Neutral Sentiment: Morgan Stanley raised its price target from $95 to $200 but kept an “equal weight” rating. The higher target is supportive, though it suggests little upside from the roughly $197 price cited in the report. Article: Morgan Stanley Raises Moderna Price Target
- Negative Sentiment: Coverage says Moderna has entered its longest losing streak since 2024, while another report characterizes the stock’s recent decline as a cooling-off after an exceptional year-to-date rally. Profit-taking and a tougher comparison after the run-up may be weighing on shares. Article: Moderna Drops, Marking Longest Losing Streak Since 2024 Article: Moderna 600% YTD Rally Catches Cold
- Negative Sentiment: Articles raised concerns about adverse reactions associated with Moderna’s mRNA flu vaccine, citing VAERS reports. These reports can flag safety signals but do not by themselves establish that the vaccine caused the events; nevertheless, the headlines may add to investor uncertainty about the product. Article: Moderna’s mRNA Influenza Vaccine and Adverse Reactions Article: Moderna’s mRNA Flu Shot Linked to Severe Adverse Events
Analysts Set New Price Targets
A number of brokerages recently commented on MRNA. Barclays raised their target price on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 24th. Morgan Stanley boosted their price target on Moderna from $95.00 to $200.00 and gave the company an “equal weight” rating in a report on Tuesday. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research report on Friday, August 28th. Evercore lifted their price objective on Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Moderna from $77.00 to $102.00 and gave the company an “underweight” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $120.25.
Get Our Latest Research Report on Moderna
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. BlackRock Inc. purchased a new position in shares of Moderna in the second quarter worth $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna during the second quarter worth $564,272,000. Wellington Management Group LLP boosted its position in shares of Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares during the last quarter. First Trust Advisors LP grew its stake in Moderna by 59.3% during the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock valued at $121,549,000 after acquiring an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. purchased a new position in Moderna during the second quarter valued at $161,642,545. 75.33% of the stock is currently owned by institutional investors.
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Read More
- Five stocks we like better than Moderna
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
